<DOC>
	<DOCNO>NCT01677754</DOCNO>
	<brief_summary>This phase II , multicenter , randomize , double-blind , parallel-group , placebo-controlled study evaluate efficacy safety RO4602522 patient moderate severity Alzheimer disease . Patients take background therapy acetylcholinesterase inhibitor alone combination memantine least 4 month screen randomize receive either one two dos RO4602522 placebo 12 month .</brief_summary>
	<brief_title>MAyflOwer RoAD Study : A Study RO4602522 Patients With Moderate Severity Alzheimer Disease Background Alzheimer Disease Therapy</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Adult patient , 5090 year age inclusive time screen Probable Alzheimer disease , base National Institute Neurological Communicative Disorders Stroke ( NINCDS ) /Alzheimer 's Disease Related Disorders Association ( ADRDA ) DSMIVTR criterion MMSE score screen 13 20 , inclusive Body mass index ( BMI ) 18 36 kg/m2 ( inclusive ) screen Modified Hachinski Ischemia Score &lt; /= 4 Patients Cornell Scale Depression Dementia ( CSDD ) score &lt; /= 13 screen Receiving treatment donepezil rivastigmine , galantamine AChEIs combination memantine least 4 month screen , dose formulation stabilize least 3 month screen . All formulation dosages allow except donezepil 23 mg ( alone combination ) Females childbearing potential must negative pregnancy test must agree use effective contraception Generally healthy ambulatory ambulatoryaided ( i.e. , walker cane ) Have reliable caregiver identify responsible person frequent contact patient Any neurological psychiatric condition may currently course study impair cognition function associate Alzheimer 's disease Background mental retardation Uncontrolled behavioral symptom incompatible compliance evaluability Alcohol and/or substance abuse dependence ( DSMIVTR ) past 2 year , except nicotine use allow . However , smoker treat nicotine replacement therapy bupropion exclude Unstable poorly control hypertension assess investigator Unstable clinically significant cardiovascular disease could expect progress , recur , change study period extent could bias assessment clinical mental status patient Inadequate hepatic , renal thyroid function Positive hepatitis B , hepatitis C HIV infection Poorly control diabetes Requiring nursing home care . Patients live assist live facility allow reliable caregiver available ( see inclusion criterion ) Current treatment AD list inclusion criterion Participation time active AD vaccine study Participation passive AD immunization study less 1 year screening , exception per protocol Psychotropic medication define protocol</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>